AGM - Our time to stand up, page-37

All true Hoyland and apologies to all for frivolous use of the word 'efficacy' - obviously that is the subject of the trial. However if bio-distribution is achieved, that is efficacy in its own way.

Regardless, our company is better positioned than ever before to create shareholder value with multiple fully-funded programs, money in the bank, milestone payments in the short tern and medium term, long term support from institutional investors who are well-connected and have deep pockets and preliminary results from a pivotal potentially ground-breaking phase 2 cancer trial due in a few months. Is this worth a punt at 16 cents?